Endovascular Ion Exchange Chemofiltration Device Reduces Off-Target Doxorubicin Exposure in a Hepatic Intra-arterial Chemotherapy Model.

Animals Doxorubicin / administration & dosage Heart Hepatic Artery Infusions, Intra-Arterial Ion Exchange Liver Swine Tissue Distribution

Journal

Radiology. Imaging cancer
ISSN: 2638-616X
Titre abrégé: Radiol Imaging Cancer
Pays: United States
ID NLM: 101765309

Informations de publication

Date de publication:
27 09 2019
Historique:
received: 08 04 2019
revised: 05 07 2019
accepted: 25 07 2019
entrez: 18 4 2020
pubmed: 18 4 2020
medline: 18 4 2020
Statut: epublish

Résumé

To determine if endovascular chemofiltration with an ionic device (ChemoFilter [CF]) can be used to reduce systemic exposure and off-target biodistribution of doxorubicin (DOX) during hepatic intra-arterial chemotherapy (IAC) in a preclinical model. Hepatic IAC infusions were performed in six pigs with normal livers. Animals underwent two 10-minute intra-arterial infusions of DOX (200 mg) into the common hepatic artery. Both the treatment group and the control group received initial IAC at 0 minutes and a second dose at 200 minutes. Prior to the second dose, CF devices were deployed in and adjacent to the hepatic venous outflow tract of treatment animals. Systemic exposure to DOX was monitored via blood samples taken during IAC procedures. After euthanasia, organ tissue DOX concentrations were analyzed. Alterations in systemic DOX exposure and biodistribution were compared by using one-tailed CF devices were well tolerated, and no hemodynamic, thrombotic, or immunologic complications were observed. Animals treated with a CF device had a significant reduction in systemic exposure when compared with systemic exposure in the control group ( Reduced systemic exposure and heart bioaccumulation of DOX during local-regional chemotherapy to the liver can be achieved through in situ adsorption by minimally invasive image-guided CF devices.© RSNA, 2019.

Identifiants

DOI: 10.1148/rycan.2019190009 PMID: 32300759 PMC: PMC7134535
pubmed: 32300759
doi: 10.1148/rycan.2019190009
pmc: PMC7134535
doi:

Substances chimiques

Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Pagination

e190009

Subventions

Organisme : NCI NIH HHS
ID : R01 CA194533
Pays : United States

Informations de copyright

2019 by the Radiological Society of North America, Inc.

Références

Cancer Lett. 2010 Dec 1;298(1):9-15
pubmed: 20573444
J Clin Oncol. 2016 Jun 10;34(17):2046-53
pubmed: 26834067
Curr Med Chem. 2009;16(25):3267-85
pubmed: 19548866
J Gastrointest Oncol. 2017 Apr;8(2):215-228
pubmed: 28480062
Cancer Control. 2017 Jan;24(1):96-101
pubmed: 28178721
J Control Release. 2016 Oct 28;240:414-433
pubmed: 26924353
Oncologist. 2000;5(5):416-24
pubmed: 11040278
Cancer Sci. 2012 Mar;103(3):528-34
pubmed: 22145922
J Hepatol. 2013 Mar;58(3):609-18
pubmed: 23041304
Am J Clin Oncol. 2018 Aug;41(8):747-753
pubmed: 28059929
J Pharmacol Exp Ther. 2006 Jun;317(3):1372-81
pubmed: 16547167
Br J Cancer. 2000 May;82(9):1539-46
pubmed: 10789721
J Gastrointest Cancer. 2016 Sep;47(3):239-46
pubmed: 27270711
Cancer. 2014 Mar 15;120(6):781-9
pubmed: 24301420
Nat Rev Clin Oncol. 2015 Jul;12(7):408-24
pubmed: 26054909
Cardiovasc Intervent Radiol. 2012 Dec;35(6):1480-7
pubmed: 22699779
Curr Pharm Des. 2016;22(28):4360-4373
pubmed: 27319945
Drug Discov Today. 2014 Dec;19(12):1855-70
pubmed: 25173702
J Med Device. 2014 Dec;8(4):0410081-410088
pubmed: 25653735
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Control Release. 2012 Jul 20;161(2):338-50
pubmed: 22285550
Cardiovasc Intervent Radiol. 2016 Jun;39(6):801-14
pubmed: 26718962
World J Hepatol. 2016 Mar 28;8(9):421-38
pubmed: 27028578
Biomed Microdevices. 2016 Dec;18(6):98
pubmed: 27778226
J Surg Res. 1986 Dec;41(6):593-9
pubmed: 3784543
Mol Pharm. 2014 Apr 7;11(4):1301-13
pubmed: 24558959
J Clin Oncol. 1992 Jan;10(1):52-60
pubmed: 1727926
Ann Surg Oncol. 2016 Apr;23(4):1309-19
pubmed: 26597368
ACS Macro Lett. 2016 Aug 16;5(8):936-941
pubmed: 27547493
Acta Pharm. 2005 Mar;55(1):81-91
pubmed: 15907226
Eur J Pharm Sci. 2011 Sep 18;44(1-2):1-10
pubmed: 21726636
Cancer J. 2010 Mar-Apr;16(2):132-41
pubmed: 20404610
Nat Commun. 2018 Jul 20;9(1):2870
pubmed: 30030447
J Pharm Pharmacol. 2017 Feb;69(2):135-142
pubmed: 27882559
Surg Clin North Am. 2016 Apr;96(2):357-68
pubmed: 27017869
Eur J Cancer. 1991;27(5):532-5
pubmed: 1647181
Cardiovasc Intervent Radiol. 2017 Aug;40(8):1196-1205
pubmed: 28451811
Surg Oncol. 1995 Aug;4(4):205-16
pubmed: 8528483

Auteurs

Colin Yee (C)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.

David McCoy (D)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.

Jay Yu (J)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.

Aaron Losey (A)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.
ORCID: 0000-0003-3433-9443

Caroline Jordan (C)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.
ORCID: 0000-0002-6483-9177

Terilyn Moore (T)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.

Carol Stillson (C)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.
ORCID: 0000-0003-0384-5183

Hee Jeung Oh (HJ)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.

Bridget Kilbride (B)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.

Shuvo Roy (S)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.

Anand Patel (A)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.

Mark W Wilson (MW)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.

Steven W Hetts (SW)

Department of Radiology and Biomedical Imaging (C.Y., D.M., J.Y., A.L., C.L., T.M., C.S., B.K., A.P., M.W.W., S.W.H.) and Department of Bioengineering and Therapeutic Sciences (S.R.), University of California, San Francisco, 505 Parnassus Ave, L-351, San Francisco, CA 94143-0628; and Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, Calif (H.J.O.).
For members of the ChemoFilter Consortium, please see the Acknowledgments.
ORCID: 0000-0001-5885-7259

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Endovascular Ion Exchange Chemofiltration...
questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Anthracyclines › Daunorubicine › Doxorubicine › Endovascular Ion Exchange Chemofiltration...
questionsmedicales.fr › Système cardiovasculaire › Coeur › Endovascular Ion Exchange Chemofiltration...
questionsmedicales.fr › Système cardiovasculaire › Vaisseaux sanguins › Artères › Artère hépatique › Endovascular Ion Exchange Chemofiltration...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Perfusions parentérales › Perfusions artérielles › Endovascular Ion Exchange Chemofiltration...
questionsmedicales.fr › Phénomènes chimiques › Échange ionique › Endovascular Ion Exchange Chemofiltration...
questionsmedicales.fr › Système digestif › Foie › Endovascular Ion Exchange Chemofiltration...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Artiodactyla › Suidae › Endovascular Ion Exchange Chemofiltration...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › Endovascular Ion Exchange Chemofiltration...